Buy this Article for $7.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Authors

  1. Aschenbrenner, Diane S. MS, APRN-BC

Abstract

* Dabigatran etexilate (Pradaxa) has been approved to lower the risk of stroke and blood clots in patients with nonvalvular atrial fibrillation.

 

* In clinical trials, patients taking dabigatran had fewer ischemic and hemorrhagic strokes than patients taking warfarin.

 

* As with other anticoagulants, dabigatran may cause serious, even fatal, bleeding.